Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 7:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 3,096 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: M.D. Anderson Cancer Center Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Reducing Tobacco Related Health Disparities

NCT00984724
View directory record Official record
Conditions
Smoking Cessation, Smoking
Interventions
Standard Treatment (ST), Telephone Counseling, Quitline, Nicotine Replacement Therapy (NRT)
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
639 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Oct 16, 2026, 7:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Determining the Tolerance of Depigmented Skin to Targeted Phototherapy Using UVB in Patients With Vitiligo

NCT00367224
View directory record Official record
Conditions
Vitiligo
Interventions
6 to 9 ultraviolet B treatments, Skin biopsies
Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 16, 2026, 7:53 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

CPRIT: Patient Adherence to Lung Cancer Screening

NCT06872723
View directory record Official record
Conditions
Lung Cancer Screening
Interventions
Lung Cancer Screening
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
50 Years to 80 Years
Enrollment
340 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 16, 2026, 7:53 PM EDT
Completed Phase 1 Interventional

Taxotere/Temodar/Cisplatin Study in Melanoma Patients

NCT00527761
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Cisplatin, Docetaxel, Temodar
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 16, 2026, 7:53 PM EDT
Recruiting Phase 1 Interventional

Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial

NCT07382726
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Adagrasib, Iza-bren
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 16, 2026, 7:53 PM EDT
Completed Phase 1 Interventional

Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients

NCT01440582
View directory record Official record
Conditions
Myeloma
Interventions
Panobinostat, Bortezomib, Lenalidomide, Dexamethasone, Symptom Questionnaire
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Oct 16, 2026, 7:53 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers Results available

A Behavioral Activation Prenatal and Postpartum Intervention for Depressed Pregnant Smokers

NCT05044546
View directory record Official record
Conditions
Depression, Tobacco Use Disorder
Interventions
Behavioral Activation Therapy, Discussion, Health Education, Questionnaire Administration, Tobacco Cessation Counseling
Behavioral · Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 16, 2026, 7:53 PM EDT
Active, not recruiting No phase listed Observational

Longitudinal Evaluation of Women Undergoing Pelvic Surgery for the Treatment of Gynecologic Cancer

NCT00791635
View directory record Official record
Conditions
Cervical Carcinoma, Endometrial Carcinoma, Malignant Female Reproductive System Neoplasm, Vaginal Carcinoma, Vulvar Carcinoma
Interventions
Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 16, 2026, 7:53 PM EDT
Recruiting Phase 1 Interventional

T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.

NCT06474676
View directory record Official record
Conditions
Metastatic Soft-tissue Sarcoma
Interventions
Cyclophosphamide, T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 16, 2026, 7:53 PM EDT
Completed Phase 2 Interventional Results available

Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy

NCT01180959
View directory record Official record
Conditions
Liver Cancer
Interventions
Bevacizumab, Erlotinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Oct 16, 2026, 7:53 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation of Single Session Stereotactic Body Radiotherapy

NCT00492817
View directory record Official record
Conditions
Spinal Neoplasms
Interventions
Stereotactic Body Radiotherapy
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 16, 2026, 7:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Very Low Nicotine Content Cigarettes and E-Cigarettes in Promoting Smoking Cessation in Daily and Intermittent Cigarette Smokers

NCT02964182
View directory record Official record
Conditions
Cigarette Smoking-Related Carcinoma, Tobacco-Related Carcinoma
Interventions
Cigarette, Nicotine Replacement, Questionnaire Administration, Survey Administration, Very Low Nicotine Content Cigarette, ECIG-Hi, ECIG-Lo
Drug · Other · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
21 Years to 65 Years
Enrollment
213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 16, 2026, 7:53 PM EDT
Not listed Phase 1 Interventional

Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

NCT03068624
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma
Interventions
Aldesleukin, Autologous CD8+ SLC45A2-specific T Lymphocytes, Cyclophosphamide, Ipilimumab
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Oct 16, 2026, 7:53 PM EDT
Completed Phase 1 Interventional

Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients

NCT02019524
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer
Interventions
E39 peptide vaccine, E39 vaccine then J65 vaccine, J65 vaccine then E39 vaccine
Biological
Lead sponsor
COL George Peoples, MD, FACS
Federal
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 16, 2026, 7:53 PM EDT
Completed No phase listed Observational

Bone Marrow Transplant Chart Review for RIC

NCT00723333
View directory record Official record
Conditions
Myelofibrosis
Interventions
Reduced Intensity Conditioning (RIC) Allogenic Transplant
Procedure
Lead sponsor
University of Utah
Other
Eligibility
60 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Houston, Texas • Salt Lake City, Utah • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 12, 2009 · Synced Oct 16, 2026, 7:53 PM EDT
Completed Phase 2 Interventional Results available

Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT01002755
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Fatigue, Fever, Hypogammaglobulinemia, Lymphadenopathy, Lymphocytosis, Night Sweats, Paraproteinemia, Small Lymphocytic Lymphoma, Thrombocytopenia
Interventions
Lenalidomide, Ofatumumab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
19 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 16, 2026, 7:53 PM EDT
Completed Phase 2 Interventional Results available

Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer

NCT00514540
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Carboplatin, Etoposide, Cisplatin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
2
States / cities
San Francisco, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 16, 2026, 7:53 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients

NCT00526110
View directory record Official record
Conditions
Gastrointestinal Diseases
Interventions
5-Fluorouracil, Docetaxel, Oxaliplatin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Oct 16, 2026, 7:53 PM EDT
Not yet recruiting Not applicable Interventional

Estimating The Rate Of Complete Ablation (A0) With The Use Of Biomechanical Deformable Image Registration

NCT07877220
View directory record Official record
Conditions
Liver Tumors
Interventions
RayAblation
Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 16, 2026, 7:53 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care

NCT03743649
View directory record Official record
Conditions
Delirium, Locally Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm
Interventions
Haloperidol, Lorazepam, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Houston, Texas • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 16, 2026, 7:53 PM EDT
Recruiting Phase 2 Interventional

Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment

NCT06617858
View directory record Official record
Conditions
Colorectal Cancer
Interventions
AMB-05X
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 16, 2026, 7:53 PM EDT
Terminated Not applicable Interventional

3T Endorectal Magnetic Resonance Spectroscopic Imaging (MRSI) of Prostate

NCT00429338
View directory record Official record
Conditions
Prostate Cancer
Interventions
AIR-MRSI, PFC-MRSI
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2015 · Synced Oct 16, 2026, 7:53 PM EDT
Completed No phase listed Observational

Survey of the Need for Information on Fertility and Menopause-Related Treatment Effects Among HSCT Patients

NCT00429455
View directory record Official record
Conditions
Stem Cell Transplantation
Interventions
Survey
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years to 50 Years · Female only
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 16, 2026, 7:53 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

NCT04902040
View directory record Official record
Conditions
Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Merkel Cell Carcinoma, Advanced Renal Cell Carcinoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Stage III Bladder Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Bladder Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Atezolizumab, Avelumab, Durvalumab, Nivolumab, Pembrolizumab, Plinabulin, Radiation Therapy
Biological · Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 16, 2026, 7:53 PM EDT